Protection from Zika virus may lie in a protein derived from mosquitoes

Phys.org | March 11, 2019

By targeting a protein found in the saliva of mosquitoes that transmit Zika virus, Yale investigators reduced Zika infection in mice. The finding demonstrates how researchers might develop a vaccine against Zika and similar mosquito-borne viruses, the study authors said. The research was published in Nature Microbiology. There is no current vaccine or therapy for Zika virus infection, which caused substantial illness, including birth defects, during the 2015 outbreak that impacted over a million people in the Americas. One source of a potential vaccine strategy is the Aedes aegypti mosquito that carries and transmits the virus. A Yale research team recently focused on proteins found in the saliva of these mosquitoes and how they might affect Zika transmission.
Led by the Section Chief for Infectious Diseases at Yale, Erol Fikrig, the team isolated antibodies from the blood of mice bitten by mosquitoes. They performed a genomic screen to identify mosquito proteins and tested the proteins for their effect in cell culture, as well as in infected mice models, against Zika virus. They pinpointed one protein, AgBR1, that exacerbated Zika infection in mice. In further experiments, the researchers examined how blocking AgBR1 might influence Zika infection. They developed an AgBR1 antiserum and gave it to mice, which were then bitten by Zika-virus-infected mosquitoes. The team observed that the antiserum reduced the level of Zika virus in the animals over time and that it also provided partial protection from full-blown disease and death.

Spotlight

SpectraMax® Paradigm® Detection Platform with TUNE cartridge, delivers 1 nm wavelength flexibility while showcasing the sensitivity of filter-based systems. Powered by our SoftMax® Pro 6 Software, your assays can be optimized in as little as half the time. Learn how by viewing our latest animation!

Spotlight

SpectraMax® Paradigm® Detection Platform with TUNE cartridge, delivers 1 nm wavelength flexibility while showcasing the sensitivity of filter-based systems. Powered by our SoftMax® Pro 6 Software, your assays can be optimized in as little as half the time. Learn how by viewing our latest animation!

Related News

RESEARCH

Prellis Biologics Announces Collaboration and License Agreement with Bristol Myers Squibb

Prellis Biologics, Inc. | January 14, 2022

Prellis Biologics, Inc. (Prellis), a Bay Area biotechnology company, announced that it has entered into a multi-target drug discovery collaboration and licensing agreement with Bristol Myers Squibb utilizing Prellis Biologics’ first-in-class externalized human immune system based on human lymph node organoids. The collaboration leverages Prellis’ EXIS platform that can break tolerance mechanisms in vitro to create high affinity human antibodies targeting human proteins. Under the terms of the agreement, Prellis and Bristol Myers Squibb will collaborate on the generation of human antibody libraries for select targets. Prellis will receive from Bristol Myers Squibb an undisclosed up-front payment, funding for research activities, development, sales milestones and royalties for licensed antibodies. "With industry leading speed, the EXIS platform provides high affinity antibodies, derived from lymph node organoids printed with Prellis’ foundational technology, using human PBMCs. We are looking forward to working with Bristol Myers Squibb to demonstrate advantages of in vitro human antibody discovery with the EXIS platform." Melanie P. Matheu, PhD, Founder and CEO of Prellis Biologics Kevin Chapman, PhD, CSO of Prellis, added, "The EXIS platform effectively breaks tolerance enabling direct discovery of human antibodies to challenging human antigens in less than two weeks." About Prellis Prellis Biologics, Inc. is the first company to develop a fully synthetic, animal-free, functional human immune system, EXIS™. The EXIS platform allows Prellis to harness fully human immune responses for the development of antibody therapeutics, disease models, and target discovery. With industry-leading speed and resolution, Prellis’ proprietary holographic printing technology is able to accurately match and rapidly replicate human organ and tissue structures. Prellis is dedicated to improving patient lives by discovering novel therapeutics, utilizing its unique capabilities in antibody discovery and in vitro human disease models. Prellis Biologics, Inc. was founded in 2016 and is a privately held company based in the San Francisco Bay Area.

Read More

Micreos Human Health Enrolles World's First Endolysin-drug as a Therapy for Atopic Dermatitis

Micreos | September 22, 2020

Dutch biotech company Micreos Human Health has enrolled the first patients in a Phase I/IIa, randomized, double-blind, placebo-controlled, parallel treated dose-ranging study to assess the safety and efficacy of XZ.700 in patients with mild to moderate atopic dermatitis. The study marks the world's first evaluation of a pharmaceutical endolysin for topical use in humans. Endolysins are highly specific enzymes that cut the bacterial cell wall, rapidly killing only the target bacteria, regardless of antibiotic resistance, while preserving the skin microbiome. XZ.700 specifically targets Staphylococcus aureus (S. aureus), a bacterium that is considered to be a causative and aggravating trigger for atopic dermatitis, and viewed as an independent cause of itch, irritation and infection. "The targeted removal of one particular bacterial species, S. aureus, from the skin microbiome, while preserving the beneficial ones is a fundamental new way to treat atopic dermatitis," says dermatologist Dr. Peter Lio, Scientific Advisor for Micreos and Scientific Advisory Board member for the National Eczema Association. XZ.700 is one of several endolysins Micreos has in its portfolio. A structurally similar endolysin, SA.100, is used in the company's over the counter (OTC) products for inflammatory skin disorders (e.g. acne and rosacea), found in the Gladskin range, which have been on the market since 2013. Data obtained in earlier Gladskin studies and feedback from doctors and thousands of customers support the pharmaceutical development program: "I am very encouraged by my experience with Gladskin and I am awaiting the findings with great anticipation." In this study, conducted in The Netherlands, XZ.700 will be tested for its safety as well as pharmacodynamics and efficacy in 48 patients with atopic dermatitis. They will be treated for 14 days with a cream containing XZ.700 at three different concentrations or placebo. Micreos expects to finish the study and report the results towards the end of 2021.

Read More

MEDTECH

Tavotek Biotherapeutics Announces Completion of Round B Financing with $35 Million

Tavotek | November 19, 2021

Tavotek Biotherapeutics, a fast-growing biotech company, announces it has raised $35M in Round B financing. CS Capital, a leading private equity fund manager in China, led this finance round followed by Fontus Capital. This round of financing will be used to accelerate the Phase 1 clinical development of several antibody drugs to start in early 2022. The upcoming antibody drugs were developed by the company based on its TavoPrecise antibody platform for various immune-related disorders. In addition, the funding will also be used to accelerate the CMC and IND development of multiple other oncology pipelines and the development of the company's multicyclic intracellular peptide (MIP) programs. Tavotek Biotherapeutics, established in early 2019, is committed to using innovation to improve the well-being of patients with unmet medical needs. The company has two R&D centers: one in Lower Gwynedd, Pennsylvania and another in Suzhou, China. The core team members have decades of successful drug development experiences at multinational pharmaceutical firms (Johnson & Johnson, Abbott/Abbvie, GlaxoSmithKline and Eli Lilly) which include many blockbuster drugs with annual sales of more than $1 billion. Tavotek's research platforms are built upon three breakthrough technologies: TavoSelect (an innovative Phage Display Library that generates conformational selective human full-length and single domain antibodies); TavoPrecise (a differentiated engineering platform for next generation tissue-specific biologics); and TavoMIP (a multicyclic peptide platform that makes undruggable targets more accessible). With the new infusion of capital, Tavotek is developing novel biologics targeting oncology and autoimmune diseases for patients. The company plans to bring multiple innovative antibodies into human clinical trials in 2022. About Tavotek Tavotek is a biopharmaceutical company focused on discovering, acquiring, developing, and commercializing medicines for patients suffering from debilitating diseases with significant unmet medical needs. Tavotek has a rich pipeline of product candidates at various stages of development for cancer, autoimmune conditions, and inflammatory diseases.

Read More